Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Operating Leases (2019 - 2025)

Spero Therapeutics (SPRO) has disclosed Operating Leases for 7 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 49.64% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Sep 2025, down 49.64%, and an annual FY2024 reading of $2.6 million, down 33.31% over the prior year.
  • Operating Leases was $1.5 million for Q3 2025 at Spero Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $6.7 million in Q1 2021 and bottomed at $1.5 million in Q3 2025.
  • Average Operating Leases over 5 years is $4.3 million, with a median of $4.4 million recorded in 2023.
  • The sharpest move saw Operating Leases surged 47.38% in 2021, then crashed 49.64% in 2025.
  • Year by year, Operating Leases stood at $6.0 million in 2021, then fell by 17.01% to $5.0 million in 2022, then dropped by 22.84% to $3.8 million in 2023, then crashed by 33.31% to $2.6 million in 2024, then tumbled by 43.08% to $1.5 million in 2025.
  • Business Quant data shows Operating Leases for SPRO at $1.5 million in Q3 2025, $1.8 million in Q2 2025, and $2.2 million in Q1 2025.